Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

PHASE3CompletedINTERVENTIONAL
Enrollment

305

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Diabetes MellitusDyslipidemias
Interventions
DRUG

Pioglitazone and Metformin

Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.

DRUG

Glimepiride and Metformin

Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.

Trial Locations (64)

Unknown

Bretten

Deggingen

Dettenheim

Künzelsau

Rottweil

Spaichingen

Stockach

Wangen

Augsburg

Feldafing

Furth im Wald

Immenstadt im Allgäu

Lichtenfels

München

Schweinfurt

Waldkraiburg

Wallerfing

Weilersbach

Würzburg

Ketzin

Rüdersdorf

Bermerhaven

Hamburg

Bensheim

Ehrenberg

Gersfeld

Kassel

Kelkheim

Offenbach

Celle

Einbeck

Hanover

Hildesheim

Schwerin

Bad Berleburg

Bad Laasphe

Bad Oeynhausen

Bocholt

Cologne

Dinslaken

Dorsten

Duisburg

Essen

Frechen

Isselburg

Kamen

Marl

Menden

Münster

Siegen

Diez

Mainz

Neuwied

Rodenbach

Simmern

Borna

Dresden

Meissen

Mittweida

Magdeburg

Reinfeld

Berlin

Altenburg

Blankenhain

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY